Trial · NCT07889232
Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer
NCT07889232, Phase 1, Phase 2, Not yet recruiting, VA Office of Research and Development
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer. Trials, record NCT07889232. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07889232
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer
- NCT number
- NCT07889232
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 43 participants, estimated
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss, Elevated Inflammatory Markers
- Interventions
- Tocilizumab, Pembrolizumab, Platinum-Doublet Chemotherapy
- First posted
- 2026-10-22
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety of adding Tocilizumab to Standard of Care Immunotherapy | From Day 1 of treatment through completion of Cycle 4 (approximately 12 weeks) | Safety: Incidence of grade ≥3 non-hematological treatment-related adverse events (TRAEs) or autoimmune toxicities. Unacceptable toxicity is defined as more than 30% incidence of grade ≥3 serious adverse events (AEs), assessed by clinical and laboratory evaluation per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. |
| Primary | Progression-Free Survival Rate | 6 months after after initiation of study treatment | Progression-Free Survival Rate at 6 months: Time from Day 1 of treatment to documented disease progression or death, assessed at 6 months per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and calculated using Kaplan Meier statistics. |
| Primary | Feasibility of Treatment Completion | From Day 1 of treatment through completion of Cycle 4 (approximately 12 weeks) | Proportion of patients completing four cycles of treatment. Feasibility is defined as ≥80% of patients completing all four cycles. |
| Secondary | Weight Change | Baseline to EOT (approximately 3 months) | Measured from baseline to end of treatment (EOT) using objective weight data. |
| Secondary | Muscle Mass | at baseline and EOT (30 +/- 7 days post last dose) | Assessed via Computed Tomography (CT) -based analysis at baseline and end of treatment. |
| Secondary | Overall Response Rate (ORR) | at EOT (approximately 3 months) | Defined as complete response (CR) + partial response (PR) per RECIST 1.1 at end of treatment. |
| Secondary | Median Overall Survivial Rate | From Day 1 of treatment until death or last follow-up (up to 12 months post-EOT) | Time from Day 1 of treatment to the point at which 50% of participants have died and 50% remain alive. |
| Secondary | Inflammatory Biomarkers | From baseline to EOT (30 +/- 7 days post last dose) | Changes in C-Reactive Protein (CRP) levels from baseline to end of treatment. |
| Secondary | Sarcopenia | at baseline and EOT (30 +/- 7 days post last dose) | Assessed via CT-based analysis at baseline and end of treatment. |
| Other | Correlation between Baseline IL-6 and Overall Response Rate (ORR) | Baseline | Evaluation of the association between baseline Interleukin-6 (IL-6) concentration and Objective Response Rate (ORR). |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07889232
GET https://conductscience.org/api/trials/v1/NCT07889232/registered?page=2